Plant Name: Piper betle
Taxonomic Information:
Plant ID: NPO26872
Plant Latin Name: Piper betle
Taxonomy Genus: Piper
Taxonomy Family: Piperaceae
Plant External Links:
NCBI TaxonomyDB:
13217
Plant-of-the-World-Online:
680605-1
Used in Medicines:
Country/Region:
Madagascar; Angola; South Africa; Indonesia; India; Zimbabwe; China; Swaziland; ThailandTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMGeographical Distribution:
Madagascar; Bangladesh; Cambodia; Swaziland; Laos; Australia; Cuba; Papua New Guinea; Zimbabwe; China; Thailand; Maldives; Philippines; Indonesia; Mauritius; Trinidad and Tobago; Vietnam; Angola; Myanmar; South Africa; India; Sri Lanka; Fiji
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| TRPA1; TRPV1; | |
| PTGS1; MAOB; | |
| HPGD; | |
| TP53; | |
| RAB9A; LMNA; NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 6.982E-08 | 1.520E-03 | CYP1A2, HPGD, MAOB, NPC1, TP53, TRPA1, TRPV1 |
| BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 1.061E-06 | 4.375E-03 | TRPA1, TRPV1 |
| BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 1.061E-06 | 4.375E-03 | TRPA1, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.206E-06 | 4.375E-03 | CYP1A2, HPGD, MAOB, NPC1, TRPV1, TSHR |
| MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 1.061E-06 | 4.375E-03 | TRPA1, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.121E-06 | 4.996E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.300E-06 | 8.243E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 7.417E-06 | 9.500E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0015278; calcium-release channel activity | 5.383E-05 | 3.663E-02 | TRPA1, TRPV1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.986E-05 | 3.950E-02 | CYP1A2, CYP3A4, PTGS1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 8.456E-06 | 5.834E-04 | MAOB, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.542E-04 | 5.846E-03 | MAOB, CYP1A2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.328E-04 | 4.581E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 4.992E-04 | 7.389E-03 | TSHR, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.354E-04 | 7.389E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 6.722E-04 | 7.730E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.519E-03 | 1.165E-02 | TRPA1, TRPV1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.470E-04 | 8.349E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.978E-03 | 1.364E-02 | MAOB, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.067E-03 | 9.204E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB; |
| NA: NA | Motor symptoms | NA | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAOB; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOB; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
